drugset
drugset / Trial / NCT00232050

Study of Omalizumab in Moderate to Severe Bronchial Asthma

NCT00232050 ↗

Phase 3 Completed 327 enrolled Novartis Daiichi Sankyo · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and efficacy of omalizumab up to 16 weeks in adult patients with moderate to severe bronchial asthma.

Timeline

Start
2002-10
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Omalizumab Monoclonal antibody — —

Indications

asthma